Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=529 A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
Cancer of Unknown Primary Site
Primary: Progression Free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1) — 6.14; 4.40 Months — p=0.0177
Phase 2 N=60 Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site
Neoplasm, Unknown Primary
Primary: Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death — 12.6 months
Phase 2 N=10 Sintilimab in Cancer of Unknown Primary
Cancer of Unknown Primary Site
Primary: Confirmed Objective Response Rate (cORR) by RECISTv1.1 — 40 percentage of participants
Phase 2 N=48 Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site
Neoplasms, Unknown Primary
Primary: Progression Free Survival — 3.7 months
Phase 2 N=35 Trial of Pembrolizumab in Cancer of Unknown Primary
Cancer of Unknown Primary Site
Primary: Overall Response Rate (ORR) by RECIST Criteria v1.1 in the Second-line & First-line Setting. — 0; 4; 9; 13 Participants
Phase 3 N=198 Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
Neoplasms, Unknown Primary
Primary: Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death — 7.4; 8.5 months
Phase 2 N=31 Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary
Carcinoma of Unknown Primary
Primary: Confirmed Response Rate (Partial or Complete Response for 2 Consecutive Evaluations at Least 4 Weeks Apart) as Measured by RECIST Criteria — 9; 13 percentage of patients…
Phase 2 N=89 Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary
Carcinoma of Unknown Primary
Primary: Progression Free Survival — 5.4; 5.3 months
Phase 2 N=46 Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Carcinoma of Unknown Primary Origin
Primary: Percentage of Participants With Confirmed Tumor Responses — 36 percentage of participants
Phase 2 N=75 Priming Immunotherapy in Advanced Disease With Radiation
Non-small Cell Lung Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Proportion of Participants Alive and Without Progression — .66 proportion of participants
Phase 2 N=36 Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Primary: Overall Response Rate (ORR) — 7; 5 percentage of participants
Phase 2 N=77 ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer
Metastatic Pancreatic Cancer
Primary: Number of Participants With Overall Response Advanced or Metastatic Pancreatic Cancer. — 0; 3 Participants
Phase 2 N=229 Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Pancreatic Adenocarcinoma
Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants
Phase 2 N=37 Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
Neuroendocrine Tumors · Neuroendocrine Neoplasm · Gastroenteropancreatic Neuroendocrine Tumor
Primary: Overall Survival Rate at 12 Months — 54.1 % of participants
Phase 2 N=100 Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
Non-small Cell Lung Carcinoma · Urothelial Carcinoma · Gastrointestinal Carcinoma, Non-colon
Primary: Overall Response Rate (ORR) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations — 10.3; 0; 7.1; 0 percentage of participants
Phase 2 N=76 Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
Breast Cancer · Chest Wall Disease
Primary: Disease Control Rate (DCR) at 18 Weeks — 20; 17 percentage of participants
Phase 2 N=61 Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
Endometrial Cancer
Primary: Progression Free Survival Differences Between Treatment Arms. — 8.049; 12.945 months
Phase 2 N=20 Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma
Metastatic Leiomyosarcoma · Unresectable Leiomyosarcoma · Uterine Corpus Leiomyosarcoma
Primary: Objective Response Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Among Patients With Advanced Leiomyosarcoma of the Uterus (ULMS) Treated With Nivolumab…
Phase 2 N=25 INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
Pancreatic Cancer Non-resectable · Pancreatic Cancer Metastatic
Primary: Disease Control Rate (DCR) at 4 Months Using RECIST 1.1 — 2 Participants
Phase 2 N=81 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma
Uterine Cancer
Primary: To Evaluate the Toxicity and Tolerability of Pelvic Radiation "Sandwiched" Between Cycles of Paclitaxel/Carboplatin Chemotherapy in Patients With UPSC — 65.5; 25.8…
Phase 2 N=647 Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Carcinoma, Non-Small-Cell Lung · Carcinoma, Small Cell Lung · Carcinoma, Thymic
Primary: Percentage of Enrolled Participants Testing Positive for Genomic Abnormality — 28.5; 44.2; 0; 24.9 percentage of participants
Phase 2 N=36 Gemzar, Cisp, Sunitinib Urothelial Ca
Urothelial Cancer
Primary: Objective Response Rate (ORR, CR+PR) in Patients With Advanced/Metastatic UC Treated With the Combination of Gemcitabine, Cisplatin, and Sunitinib. — 48.5 Percentage of…
Phase 2 N=8 Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
Urothelial Carcinoma · Bladder Cancer · Urinary Bladder Neoplasms
Primary: Percentage of Participants Who Enrolled and Underwent a Biopsy Who Went on to Receive Treatment Within 21 Days — 63 percentage of participants
Phase 2 N=28 Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC) · Stage IV NSCLC · Metastatic NSCLC
Primary: Objective Response Rate — 0; 1 participants
Phase 2 N=100 Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer
Advanced Metastatic Cancer · Advanced Prostate Cancer
Primary: Clinical Benefit Rate (CBR) of Nivolumab With or Without Ipilimumab — 1; 18; 1; 1 Participants
Phase 2 N=515 Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
Gastric Adenocarcinoma · Esophageal Cancer · Hepatocellular Carcinoma
Primary: Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events — 100.0; 100.0; 100.0; 99.8 Percentage of…
N/A N=90 Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Synchronous Metastasized Breast Cancer · Circulating Tumor Cells
Primary: Overall Survival (OS) — 34.6; 56.2 months — p=0.042
Phase 2 N=13 Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Response Rate — 1; 2; 4 participants
Phase 2 N=3 Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer
Cancer
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 1; 2 Participants